Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$21.24 USD
+0.08 (0.38%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $21.23 -0.01 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.24 USD
+0.08 (0.38%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $21.23 -0.01 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Zacks News
Stevanato Group S.p.A. (STVN) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Stevanato (STVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Teleflex (TFX) Urolift Market Expansion Strong, Cost Woe Stays
by Zacks Equity Research
Teleflex (TFX) plans to spend 2023 training surgeons, building its presence in key cities and continuing to engage with the Chinese Urological Society to build acceptance.
Thermo Fisher (TMO) Partners With ArsenalBio for Cancer R&D
by Zacks Equity Research
Thermo Fisher's (TMO) latest collaboration with ArsenalBio supports the latter's clinical manufacturing of autologous T-cell therapies for advanced cancer treatment.
Masimo (MASI) Unveils Freedom Smartwatch With Privacy Switch
by Zacks Equity Research
Masimo's (MASI) newest wearable product seamlessly integrates continuous health tracking technology and breakthrough features.
Insulet (PODD) Benefits From Omnipod 5 Launch, Expansion
by Zacks Equity Research
Insulet (PODD) witnesses continued uptake of Omnipod through the U.S. pharmacy channel.
CVS Health (CVS) Nears Completion of $8B SGFY Acquisition
by Zacks Equity Research
According to CVS Health (CVS), Signify Health, a leading healthcare platform, is set to play a critical role in advancing its healthcare services strategy.
Thermo Fisher (TMO) Opens New Cell Therapy Facility at UCSF
by Zacks Equity Research
Thermo Fisher's (TMO) new cell therapy facility at UCSF is likely to accelerate the development of advanced therapies.
Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Catalyst Pharmaceutical (CPRX) closed at $16.44, marking a +1.99% move from the previous day.
Encompass Health (EHC) Opens JV Hospital for Oklahoma Patients
by Zacks Equity Research
Encompass Health (EHC) inaugurated the Owasso-based Ascension St. John Rehabilitation Hospital, that it will operate jointly with Ascension St. John to offer rehabilitative care in Oklahoma.
Walgreens Boots (WBA) Benefits From Innovation Amid Margin Woe
by Zacks Equity Research
Walgreens Boots' (WBA) comparable pharmacy sales decline reflects lower demand for COVID-19 services.
Abbott's (ABT) CardioMEMS Favors Heart Failure Management
by Zacks Equity Research
Abbott (ABT) announces key findings from meta-analysis, which shows remote pressure monitoring to be a life-extending option among heart failure patients.
Globus Medical (GMED) to Gain From NUVA Deal Amid Rising Costs
by Zacks Equity Research
The NuVasive acquisition aims to outpace market growth by combining Globus Medical's (GMED) engineering and NuVasive's relations, education and training.
Smith & Nephew's (SNN) CIT Technology Favored by New Study
by Zacks Equity Research
Smith & Nephew (SNN) achieves a positive response for its COBLATION-Technology-infused Intracapsular Tonsillectomy Technique, providing fast patient recovery over existing surgeries.
Syneos Health (SYNH) Partners With KX for Data-Driven Insights
by Zacks Equity Research
Syneos Health's (SYNH) partnership with KX is likely to accelerate clinical trial execution using AI-enabled solutions.
Wall Street Analysts Think Catalyst (CPRX) Could Surge 26.44%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Henry Schein (HSIC) Bolsters Dental Practices With AI Tools
by Zacks Equity Research
Henry Schein (HSIC) integrates AI-enabled solutions, Dentrix Ascend Detect AI and Dentrix Ascend Voice, into its cloud-based dental software.
Zacks.com featured highlights include Catalyst Pharmaceuticals, Terex and Arista Networks
by Zacks Equity Research
Catalyst Pharmaceuticals, Terex and Arista Networks are part of the Zacks Screen of the Week article.
Catalyst Pharmaceutical (CPRX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Catalyst Pharmaceutical (CPRX) closed at $16.53 in the latest trading session, marking a +0.79% move from the prior day.
Select Medical's (SEM) Orlando Facility to Boost Post-Acute Care
by Zacks Equity Research
Select Medical (SEM) aims to address the post-acute care demand in the Central Florida region through the construction of a specialty hospital in Orlando.
Is Trending Stock Catalyst Pharmaceuticals, Inc. (CPRX) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Catalyst (CPRX). This makes it worthwhile to examine what the stock has in store.
3 Stocks With Solid Earnings Growth to Buy Right Away
by Tirthankar Chakraborty
Invest in stocks like Catalyst Pharmaceuticals (CPRX), Terex (TEX) & Arista Networks (ANET) at the moment for superb earnings growth.
Is It Worth Investing in Catalyst (CPRX) Based on Wall Street's Bullish Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Catalyst (CPRX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
3 Reasons Why Growth Investors Shouldn't Overlook Catalyst (CPRX)
by Zacks Equity Research
Catalyst (CPRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Catalyst's (CPRX) Q4 Earnings & Sales Top, Boosted by Firdapse
by Zacks Equity Research
Catalyst Pharmaceuticals (CPRX) reports better-than-expected financial performance as it beats both earnings and revenue estimates. Firdapse sales continue to grow year over year.
Catalyst Pharmaceutical (CPRX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 4.76% and 0.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?